Boxer Capital’s Genocea Biosciences, Inc. GNCA Stock Holding History

Boxer Capital’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,134,453	Closed	-$1.42M	–	79
2022 Q1	$1.42M	Hold	1,134,453	–	–	0.07%	69
2021 Q4	$1.32M	Hold	1,134,453	–	–	0.05%	69
2021 Q3	$2.18M	Hold	1,134,453	–	–	0.08%	81
2021 Q2	$2.65M	Hold	1,134,453	–	–	0.09%	87
2021 Q1	$3.07M	Hold	1,134,453	–	–	0.1%	78
2020 Q4	$2.75M	Hold	1,134,453	–	–	0.09%	73
2020 Q3	$2.6M	Buy	+1,134,453	New	+$2.98M	0.09%	73

Other funds holding GNCA

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Boxer Capital's GNCA Position: Q2 2022 in Review

Boxer Capital sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 1,134,453 shares — an estimated $1.42M sold.

Boxer Capital first reported a position in GNCA in Q3 2020 and held it in 7 quarters. The position peaked at $3.07M in Q1 2021. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.

Boxer Capital reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
Boxer Capital sold 1,134,453 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $1.42M.
Boxer Capital first reported a position in Genocea Biosciences, Inc. in Q3 2020 and held it in 7 quarters.
Boxer Capital's Genocea Biosciences, Inc. position peaked at $3.07M in Q1 2021.
5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.

Based on Boxer Capital's 13F filing for Q2 2022, filed 15 Aug 2022.